Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 95

Similar articles for PubMed (Select 22751280)

1.

Targeted therapies: pazopanib for soft-tissue sarcoma: a PALETTE of data emerges.

Ray-Coquard I, Thomas D.

Nat Rev Clin Oncol. 2012 Jul 3;9(8):431-2. doi: 10.1038/nrclinonc.2012.113. No abstract available.

PMID:
22751280
2.

Differences in the responses to pazopanib and the prognoses of soft tissue sarcomas by their histological eligibility for the PALETTE study.

Nakano K, Motoi N, Inagaki L, Tomomatsu J, Gokita T, Ae K, Tanizawa T, Shimoji T, Matsumoto S, Takahashi S.

Jpn J Clin Oncol. 2015 May;45(5):449-55. doi: 10.1093/jjco/hyv022. Epub 2015 Feb 26.

PMID:
25724217
3.

Pazopanib in sarcomas: expanding the PALETTE.

Wilky BA, Meyer CF, Trent JC.

Curr Opin Oncol. 2013 Jul;25(4):373-8. doi: 10.1097/CCO.0b013e3283622d3a. Review.

4.

Pazopanib in the treatment of soft tissue sarcoma.

Schöffski P.

Expert Rev Anticancer Ther. 2012 Jun;12(6):711-23. doi: 10.1586/era.12.41. Review.

PMID:
22716487
5.

Long-term responders and survivors on pazopanib for advanced soft tissue sarcomas: subanalysis of two European Organisation for Research and Treatment of Cancer (EORTC) clinical trials 62043 and 62072.

Kasper B, Sleijfer S, Litière S, Marreaud S, Verweij J, Hodge RA, Bauer S, Kerst JM, van der Graaf WT.

Ann Oncol. 2014 Mar;25(3):719-24. doi: 10.1093/annonc/mdt586. Epub 2014 Feb 6.

6.

Pazopanib: in advanced soft tissue sarcoma.

Deeks ED.

Drugs. 2012 Nov 12;72(16):2129-40. doi: 10.2165/11209950-000000000-00000.

PMID:
23072642
7.

Pazopanib, a new therapy for metastatic soft tissue sarcoma.

Verweij J, Sleijfer S.

Expert Opin Pharmacother. 2013 May;14(7):929-35. doi: 10.1517/14656566.2013.780030. Epub 2013 Mar 14. Review.

PMID:
23488774
8.

Clinical trial end points for assessing efficacy of novel therapies for soft-tissue sarcomas.

Chmielowski B, Federman N, Tap WD.

Expert Rev Anticancer Ther. 2012 Sep;12(9):1217-28. doi: 10.1586/era.12.100. Review.

PMID:
23098121
9.

Pazopanib and the treatment palette for soft-tissue sarcoma.

Bramwell VH.

Lancet. 2012 May 19;379(9829):1854-6. doi: 10.1016/S0140-6736(12)60739-9. Epub 2012 May 16. No abstract available.

PMID:
22595798
10.

Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043).

Sleijfer S, Ray-Coquard I, Papai Z, Le Cesne A, Scurr M, Schöffski P, Collin F, Pandite L, Marreaud S, De Brauwer A, van Glabbeke M, Verweij J, Blay JY.

J Clin Oncol. 2009 Jul 1;27(19):3126-32. doi: 10.1200/JCO.2008.21.3223. Epub 2009 May 18.

11.

Pazopanib: a promising new agent in the treatment of soft tissue sarcomas.

Kasper B, Hohenberger P.

Future Oncol. 2011 Dec;7(12):1373-83. doi: 10.2217/fon.11.116.

PMID:
22112314
12.

Nursing considerations with pazopanib therapy: focus on metastatic renal cell carcinoma.

Bourdeanu L, Twardowski P, Pal SK.

Clin J Oncol Nurs. 2011 Oct;15(5):513-7. doi: 10.1188/11.CJON.513-517.

PMID:
21951737
13.

Pazopanib: the newest tyrosine kinase inhibitor for the treatment of advanced or metastatic renal cell carcinoma.

Keisner SV, Shah SR.

Drugs. 2011 Mar 5;71(4):443-54. doi: 10.2165/11588960-000000000-00000. Review.

PMID:
21395357
14.

[Pharmacological profile and clinical results in advanced soft tissue sarcoma patients of pazopanib hydrochloride (Votrient(®))].

Arai H, Fukasawa N, Ueta F.

Nihon Yakurigaku Zasshi. 2013 Jan;141(1):37-42. Review. Japanese. No abstract available.

PMID:
23302947
15.

Pazopanib a tyrosine kinase inhibitor with strong anti-angiogenetic activity: a new treatment for metastatic soft tissue sarcoma.

Ranieri G, Mammì M, Donato Di Paola E, Russo E, Gallelli L, Citraro R, Gadaleta CD, Marech I, Ammendola M, De Sarro G.

Crit Rev Oncol Hematol. 2014 Feb;89(2):322-9. doi: 10.1016/j.critrevonc.2013.08.012. Epub 2013 Sep 4. Review.

PMID:
24041629
16.

Pazopanib for metastatic soft-tissue sarcoma.

Endo M, Nielsen TO.

Lancet. 2012 Sep 1;380(9844):801; author reply 801. doi: 10.1016/S0140-6736(12)61440-8. No abstract available.

PMID:
22939674
17.

[Pazopanib (Votrient) in the management of renal cell cancer and soft tissue sarcomas].

Gennigens C, Jerusalem G.

Rev Med Liege. 2012 Jul-Aug;67(7-8):437-42. French.

PMID:
22984765
18.

Complete pathologic response in soft tissue sarcoma lung metastases with pazopanib.

Eroglu Z, Kim J, Wilczynski S, Chow WA.

J Thorac Oncol. 2014 Jan;9(1):e4-6. doi: 10.1097/JTO.0b013e3182a4700d. No abstract available.

PMID:
24346105
19.

A novel multi-kinase inhibitor pazopanib suppresses growth of synovial sarcoma cells through inhibition of the PI3K-AKT pathway.

Hosaka S, Horiuchi K, Yoda M, Nakayama R, Tohmonda T, Susa M, Nakamura M, Chiba K, Toyama Y, Morioka H.

J Orthop Res. 2012 Sep;30(9):1493-8. doi: 10.1002/jor.22091. Epub 2012 Feb 22.

PMID:
22359392
20.

Pazopanib in renal cell carcinoma.

Ward JE, Stadler WM.

Clin Cancer Res. 2010 Dec 15;16(24):5923-7. doi: 10.1158/1078-0432.CCR-10-0728. Epub 2010 Nov 8. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk